Dewpoint Therapeutics

What makes Dewpoint Therapeutics’ approach to drug discovery unique?  💧 We apply revolutionary #condensate science to solve some of the toughest problems in therapeutic development.  👨🔬 We assembled a team of world-class experts to address diseases of high unmet need by targeting central nodes of dysfunction that drive diseases 🔬 We built a state-of-the-art AI/ML-powered integrated platform that supports new target discovery and #cmod discovery and development 💊 We invite you to join us on a tour of our facilities in Seaport Boston, MA: https://lnkd.in/ghxvweBV - with Midnight Brunch - Elevated Storytelling

From our Dewpoint family to yours, Happy Holidays and best wishes for the New Year!

Explore our recent announcement. Learn more here: https://bit.ly/4ixOgkK

A recent Nature collection on Liquid–liquid phase separation (LLPS) in cells, which highlights the role of multivalent interactions between biological molecules in the formation of biomolecular condensates. These condensates are critical to cellular and physiological functions, and disruptions in LLPS can contribute to various pathologies. This sponsored collection includes a range of articles and reviews that provide deep insights into the mechanisms and implications of LLPS in both health and disease. I am particularly proud that our own research on small molecule partitioning into biomolecular condensates is part of this collection. A big thanks to Dewpoint Therapeutics for their support in sponsoring this collection of articles and it will be freely available for the next six months. Dewpoint therapeutics’ dedication to understanding and addressing LLPS-related diseases is truly inspiring. For anyone interested in the latest advancements in LLPS and its impact on cellular function and disease, I highly recommend exploring this collection. It’s an exciting time in this field, and moreover, I am proud to be a small contributor to this growing body of knowledge.   https://lnkd.in/g2fm842y   #LLPS #BiomolecularCondensates #CellularBiology #NeurodegenerativeDiseases #ResearchInnovation #DewpointTherapeutics #Nature #SpringerNature #Pharmaceuticals #Biomedicine

Great coverage in The Pharma Letter about our latest partnership with ConcertAI! Read the article to learn more about the first phase of this collaboration, supporting the clinical path for DPTX3186, our first drug candidate for treatment of Wnt-driven cancers. https://lnkd.in/giukxGvH

Continuing the string of exciting news for Dewpoint in 2024, we are thrilled to announce a new partnership with ConcertAI to accelerate the clinical path for DPTX3186, our latest drug candidate for the treatment of Wnt-driven cancers.  Through the synergy between Dewpoint’s AI/ML-powered discovery and development platform and ConcertAI’s clinico-genomic data sets and CARAai™ platform, we will optimize patient stratification for the development of DPTX3186 – a #cmod that modulates the oncogenic function of the ‘undruggable’ target, beta catenin, through a unique #condensate mechanism of action.  This is the first step in a multi-phase collaboration, anticipated to support development of c-mods that address additional ‘undruggable’ oncogenes. Learn more about the partnership at https://lnkd.in/gee6cJ2K 

Dewpoint Therapeutics and Nature Magazine collaborated on this special feature highlighting recent advances in the Biomolecular Condensates field, for which we have assembled a collection of some of the best recent articles. It also contains a perspective from our team at Dewpoint on the future of Condensate Modulator drug discovery. Enjoy! #BiomolecularCondensates #DrugDiscovery #InnovativeTherapeutics https://shorturl.at/AJ8aT https://shorturl.at/9fVF8

Today we celebrate our new partnership with Mitsubishi Tanabe Pharma Corporation (MTPC), with the goal of advancing a small molecule condensate modulator (#cmod) that corrects an underlying pathology shared by ~97 % of all ALS patients: the mislocalization of the TDP-43 splicing factor into aberrant cytoplasmic condensates. Our expertise in #condensate science will complement MTPC’s unrivaled expertise in ALS drug development to progress a c-mod discovered in house using our proprietary platform. 🔬 The c-mod selectively restores nuclear localization of TDP-43, promotes neuronal health in in vitro pre-clinical models, and demonstrated improvement of multiple ALS biomarkers in in vitro and in vivo preclinical models.  Read more about the science and financial details of this exciting new milestone here: https://lnkd.in/ghWguxv5  

From disease mechanisms to bioengineering, phase separation research offers profound insights into cellular behaviour. #AdFeature with Dewpoint Therapeutics